AR044974A1 - Derivados duales de nk1/nk3, su uso, procedimiento de preparacion y medicamento para el tratamiento de la esquizofrenia - Google Patents

Derivados duales de nk1/nk3, su uso, procedimiento de preparacion y medicamento para el tratamiento de la esquizofrenia

Info

Publication number
AR044974A1
AR044974A1 ARP040102313A ARP040102313A AR044974A1 AR 044974 A1 AR044974 A1 AR 044974A1 AR P040102313 A ARP040102313 A AR P040102313A AR P040102313 A ARP040102313 A AR P040102313A AR 044974 A1 AR044974 A1 AR 044974A1
Authority
AR
Argentina
Prior art keywords
alkyl
unsubstituted
halogen
substituted
lower alkyl
Prior art date
Application number
ARP040102313A
Other languages
English (en)
Inventor
Torsten Hoffmann
Andreas Koblet
Jens-Uwe Peters
Patrick Schnider
Andrew Sleight
Heinz Stadler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33560750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR044974(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR044974A1 publication Critical patent/AR044974A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/547—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D419/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Reivindicación 1: El uso de compuestos de la fórmula general (1), en donde: R1 es arilo, sin sustituir o sustituido por uno o más sustituyentes, seleccionados del grupo, consistente en alquilo inferior, alcoxilo inferior, halógeno, -(CH2)oOH, -C(O)H, CF3, CN, S-alquilo inferior, -S(O)-alquilo inferior, -C(O)NR'R'', -NR'R'', -NR'C(O)-alquilo inferior, -NR'S(O)2-alquilo inferior, o es heteroarilo, seleccionados de los grupos, consistentes en piridin-2- ó 3-ilo, imidazolilo u oxazolilo, sin sustituir o sustituido por alquilo inferior, halógeno o alcoxilo; R2 y R3 son independientemente el uno del otro hidrógeno, halógeno, alquilo, alcoxilo, OCHF2, OCH2F, OCF3 ó CF3; R4, R5 son independientemente el uno del otro hidrógeno, -(CR'R'')1-(CR'R'')1-(CR'R'')0,1-OH ó -(CR'R'')1-(CR'R'')1-(CR'R'')0,1-alquilo inferior, en donde R' y R'' en cada átomo de carbono puede ser el mismo o diferente el uno del otro, -C1,2-alquilo; -C(O)H; -(CH)2ocicloalquilo, sin sustituir o sustituido por hidroxilo; -(CH2)1,2,3NR'R''; -(CH2)1,2,3NR'C(O)-alquilo inferior; -(CH2)1,2,3NR'S(O)2-alquilo inferior; -(CH2)oS(O)-alquilo inferior; R' es hidrógeno, alquilo inferior, -(CH2)oOH, -C(O)H, -C(O)-alquilo inferior, -C(O)-cicloalquilo, -S(O)2-alquilo inferior; R'' es hidrógeno o alquilo inferior; o R4 y R5 forman junto con el átomo N al que están unidos un anillo con: -(CH2)3-5-, que está sin sustituir o sustituido por uno o más sustituyentes, seleccionados del grupo consistente en alquilo, halógeno, -(CR'R'')oOH, =O, -CHO, -NR'R'', en donde R' y R'' pueden formar junto con el átomo N al que están unidos un anillo con -(CH2)3-5, o mediante -(CH2)oNR'-C(O)-alquilo, -(CH2)o-C(O)-alquilo inferior, -(CH2)o-C(O)-cicloalquilo, -(CH2)oOC-(O)NR'R'', -(CH2)o-S(O)2-alquilo, -(CH2)o-S(O)-alquilo inferior, -(CH2)o-S-alquilo inferior, -(CH2)o-S(O)2-NR'R'', -(CH2)o-pirrolidinilo, o -C(O)NR'R'', o con -(CH2)1,2,3-NR'-(CH2)2-, que está sin sustituir o sustituido por uno o más sustituyentes, seleccionados del grupo consistente en alquilo inferior, halógeno, CF3, -(CR'R'')oOH, =O, -CHO, -NR'R'', en donde R' y R'' pueden formar junto con el átomo N al que están unidos un anillo con -(CH2)3-5, o mediante -(CH2)oNR'-C(O)-alquilo inferior, -(CH2)o-C(O)-alquilo inferior, -(CH2)o-C(O)-cicloalquilo, -(CH2)oOC(O)NR'R'', -(CH2)o-S(O)2-alquilo inferior, -(CH2)o-pirrolidinilo o -C(O)NR'R'', o con -(CH2)1,2,3-O-(CH2)2-, que está sin sustituir o sustituido por uno o más sustituyentes, seleccionados del grupo consistente en alquilo, halógeno, -(CR'R'')oOH, =O, -CHO, -NR'R'', en donde R' puede formar junto con el átomo N al que están unidos un anillo con -(CH2)3-5, o mediante -(CH2)oNR'-C(O)-alquilo inferior , -(CH2)o-C(O)-alquilo inferior, -(CH2)o-C(O)-cicloalquilo, -(CH2)oOC(O)NR'R'', -(CH2)o-S(O)2-alquilo inferior, -(CH2)o-pirrolidinilo o -C(O)NR'R'', o con -(CH2)1,2,3-S(O)0,1,2-(CH2)1,2,3-, que está sin sustituir o sustituido por uno o más sustituyentes, seleccionados del grupo consistente en alquilo inferior, halógeno, CF3, -(CR'R'')oOH, =O, -NR'R'', en donde R' y R'' pueden formar junto con el átomo N- al que están unidos un anillo con -(CH2)3-5, o -(CH2)oNR'-C(O)-alquilo inferior, -(CH2)o-C(O)-alquilo, -(CH2)o-C(O)-cicloalquilo, -(CH2)oOC(O)NR'R'', -(CH2)o-S(O)2-alquilo inferior, -(CH2)o-pirrolidi-nilo o -C(O)NR'R'', o con -CH2CH=CH-CH2-, que está sin sustituir o sustituido por uno o más sustituyentes, seleccionados del grupo consistente en alquilo, halógeno, -(CR'R'')oOH, =O, -CHO, -NR'R'', en donde R' y R'' pueden formar junto con el átomo N al que está unido un anillo con -(CH2)3-5, o mediante -(CH2)oNR'-C(O)-alquilo inferior, -(CH2)o-C(O)-alquilo inferior, -(CH2)o-C(O)-cicloalquilo, -(CH2)oOC(O)NR'R'', -(CH2)o-S(O)2-alquilo inferior, -(CH2)o-pirrolidinilo o -C(O)NR'R'', o es 0, 1, 2, ó 3 o sales de adición ácida farmacéuticamente activas de los mismos, para la preparación de medicamentos para el tratamiento de esquizofrenia.
ARP040102313A 2003-07-03 2004-07-01 Derivados duales de nk1/nk3, su uso, procedimiento de preparacion y medicamento para el tratamiento de la esquizofrenia AR044974A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03014513 2003-07-03

Publications (1)

Publication Number Publication Date
AR044974A1 true AR044974A1 (es) 2005-10-12

Family

ID=33560750

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102313A AR044974A1 (es) 2003-07-03 2004-07-01 Derivados duales de nk1/nk3, su uso, procedimiento de preparacion y medicamento para el tratamiento de la esquizofrenia

Country Status (27)

Country Link
US (3) US20050090533A1 (es)
EP (1) EP1643998B1 (es)
JP (1) JP4490421B2 (es)
KR (1) KR100744859B1 (es)
CN (1) CN1852712B (es)
AR (1) AR044974A1 (es)
AT (1) ATE371451T1 (es)
AU (1) AU2004253267B2 (es)
BR (1) BRPI0412291A (es)
CA (1) CA2530886C (es)
CO (1) CO5650234A2 (es)
DE (1) DE602004008631T2 (es)
DK (1) DK1643998T3 (es)
ES (1) ES2291891T3 (es)
HR (1) HRP20070471T3 (es)
IL (1) IL172614A (es)
MX (1) MXPA06000192A (es)
MY (1) MY137156A (es)
NO (1) NO20056007L (es)
NZ (1) NZ544244A (es)
PL (1) PL1643998T3 (es)
PT (1) PT1643998E (es)
RU (1) RU2347777C2 (es)
SI (1) SI1643998T1 (es)
TW (1) TW200502230A (es)
WO (1) WO2005002577A1 (es)
ZA (1) ZA200510453B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004034619A1 (de) * 2004-07-16 2006-02-23 Grünenthal GmbH Substituierte Aminoverbindungen als 5-HT/NA Uptakehemmer
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
DE102004039789A1 (de) * 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES2540966T3 (es) 2005-02-16 2015-07-15 Anacor Pharmaceuticals, Inc. Compuestos biocidas de boronoftalida
ES2329827T3 (es) * 2005-02-22 2009-12-01 F. Hoffmann-La Roche Ag Antagonistas de nk1.
CN101146775B (zh) * 2005-03-23 2012-07-18 弗·哈夫曼-拉罗切有限公司 用于呕吐的用作nk-i拮抗剂的代谢物
WO2006119390A1 (en) * 2005-05-04 2006-11-09 Vertex Pharmaceuticals Incorporated Pyridines useful as modulators of ion channels
US7880008B2 (en) * 2005-05-31 2011-02-01 Vertex Pharmaceuticals Incorporated Heterocycles useful as modulators of ion channels
DK1928886T3 (da) * 2005-09-09 2011-07-11 Glaxosmithkline Llc Pyridin-derivater og deres anvendelse i behandlingen af psykotiske lidelser
GB0518472D0 (en) * 2005-09-09 2005-10-19 Glaxo Group Ltd Novel compounds
WO2007039123A2 (en) * 2005-09-22 2007-04-12 Smithkline Beecham Corporation Combination therapy comprising an nk-3 antagonist and an antipsychotic agent
BRPI0621279B1 (pt) 2005-12-30 2021-07-20 Anacor Pharmaceuticals, Inc Moléculas pequenas contendo boro
CN102532180B (zh) * 2005-12-30 2016-06-29 安纳考尔医药公司 含硼的小分子
EP2007726B1 (en) 2006-02-07 2011-03-02 F. Hoffmann-La Roche AG Benzamide and heteroarene derivatives as cetp inhibitors
CA2682506C (en) * 2007-04-20 2016-05-24 F. Hoffmann-La Roche Ag Pyrrolidine derivatives as dual nk1/nk3 receptor antagonists
CN101778837A (zh) 2007-08-07 2010-07-14 弗·哈夫曼-拉罗切有限公司 作为nk3受体拮抗剂的吡咯烷芳基-醚
GB0808747D0 (en) * 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
GB0814340D0 (en) 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
CA2772168C (en) * 2009-08-27 2019-01-08 Glaxosmithkline Llc Anhydrate forms of a pyridine derivative
WO2011054773A1 (en) 2009-11-03 2011-05-12 Glaxosmithkline Llc Novel lactam compounds
US20110144081A1 (en) * 2009-12-15 2011-06-16 Henner Knust Pyrrolidine derivatives
US8487102B2 (en) 2010-04-20 2013-07-16 Hoffmann-La Roche Inc. Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
CA2930008A1 (en) * 2013-11-08 2015-05-14 Kissei Pharmaceutical Co., Ltd. Carboxymethyl piperidine derivative
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
CN114306347A (zh) 2015-05-18 2022-04-12 康堤医疗有限公司 用于治疗性激素依赖性疾病的双重nk-1/nk-3受体拮抗剂
HUE049979T2 (hu) 2017-03-20 2020-11-30 Forma Therapeutics Inc Pirrolopirrol készítmények piruvát-kináz (PKR) aktivátorokként
MX2020009438A (es) 2018-03-14 2022-05-11 Kandy Therapeutics Ltd Formulacion farmaceutica novedosa que comprende antagonistas del receptor dual nk-1/nk-3.
BR112021005188A2 (pt) 2018-09-19 2021-06-08 Forma Therapeutics, Inc. tratamento de anemia falciforme com um composto de ativação de piruvato cinase r
CN113226356A (zh) 2018-09-19 2021-08-06 福马治疗股份有限公司 活化丙酮酸激酶r
CN114728906B (zh) 2019-11-15 2024-08-20 康堤医疗有限公司 制备nt-814的关键中间体6-氯-4-(4-氟-2-甲基苯基)吡啶-3-胺的新化学方法
EP4431512A1 (en) 2023-03-16 2024-09-18 Bayer Consumer Care AG Novel dual nk-1/nk-3 receptor antagonists

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
SG52217A1 (en) 1993-12-29 1998-09-28 Merck Sharp & Dohme Substituted morpholine derivatives and their use as therapeutic agents
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
FR2719311B1 (fr) * 1994-03-18 1998-06-26 Sanofi Sa Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.
WO1998024445A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating schizophrenic disorders
US5972938A (en) * 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
WO2000050398A2 (en) 1999-02-24 2000-08-31 F. Hoffmann-La Roche Ag Phenyl- and pyridinyl derivatives as neurokinin 1 antagonists
EP1035115B1 (en) * 1999-02-24 2004-09-29 F. Hoffmann-La Roche Ag 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
PT1103545E (pt) 1999-11-29 2004-03-31 Hoffmann La Roche 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-totil-piridin-3-il)-isobutiramida
KR100501608B1 (ko) * 2000-07-14 2005-07-18 에프. 호프만-라 로슈 아게 4-페닐-피리딘 유도체의 ｎｋ1 수용체의 길항성선구약물로서의 ｎ-산화물
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
EP1192952A3 (en) 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
KR100599134B1 (ko) * 2001-04-23 2006-07-12 에프. 호프만-라 로슈 아게 양성 전립선 비대증에 대한 ｎｋ-1 수용체 길항물질의 용도
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury

Also Published As

Publication number Publication date
NO20056007L (no) 2006-01-19
AU2004253267A1 (en) 2005-01-13
CN1852712B (zh) 2010-06-09
US7939533B2 (en) 2011-05-10
CA2530886C (en) 2013-05-28
EP1643998A1 (en) 2006-04-12
WO2005002577A1 (en) 2005-01-13
MXPA06000192A (es) 2006-04-11
EP1643998B1 (en) 2007-08-29
CN1852712A (zh) 2006-10-25
SI1643998T1 (sl) 2007-12-31
ZA200510453B (en) 2007-01-31
AU2004253267B2 (en) 2008-12-04
US20050090533A1 (en) 2005-04-28
DE602004008631D1 (de) 2007-10-11
RU2006103010A (ru) 2007-08-10
IL172614A0 (en) 2006-04-10
KR20060030893A (ko) 2006-04-11
DE602004008631T2 (de) 2008-07-10
US8404708B2 (en) 2013-03-26
CO5650234A2 (es) 2006-06-30
ES2291891T3 (es) 2008-03-01
US20110178055A1 (en) 2011-07-21
JP2009500290A (ja) 2009-01-08
RU2347777C2 (ru) 2009-02-27
JP4490421B2 (ja) 2010-06-23
US20090137806A1 (en) 2009-05-28
PT1643998E (pt) 2007-11-21
PL1643998T3 (pl) 2008-01-31
CA2530886A1 (en) 2005-01-13
TW200502230A (en) 2005-01-16
IL172614A (en) 2010-12-30
MY137156A (en) 2008-12-31
NZ544244A (en) 2008-10-31
ATE371451T1 (de) 2007-09-15
DK1643998T3 (da) 2007-12-27
BRPI0412291A (pt) 2006-09-19
HRP20070471T3 (en) 2007-11-30
KR100744859B1 (ko) 2007-08-01

Similar Documents

Publication Publication Date Title
AR044974A1 (es) Derivados duales de nk1/nk3, su uso, procedimiento de preparacion y medicamento para el tratamiento de la esquizofrenia
AR029717A1 (es) Derivados del pro-farmaco de 4-fenil-piridina
UY26043A1 (es) Acidos oxamicos y derivados como ligandos de receptores tiroideos
JPS62126168A (ja) 新規化合物、その製法及びそれを含む医薬組成物
AR045859A1 (es) Derivados de dibenzoazepina y de benzodiazepinas sustitudos, procesos de preparacion y usos
AR037489A1 (es) Quinolinas sustituidas y proceso para su preparacion
AR052903A1 (es) Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de trastornos del sueno.
AU2003212305A1 (en) Cyclic amides
AR059328A1 (es) Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp
AR050282A1 (es) Antagonistas duales nk1/nk3 contra la esquizofrenia
MX2009011051A (es) Derivados de pirrolidina como antagonistas del receptor nk1/nk3 doble.
PT736525E (pt) Benzonitrilos e fluoretos como agonistas e antagonistas de 5-ht
AR041079A1 (es) Derivados de 2-ariltiazol como agonistas de receptores activados proliferadores de peroxisomas alfa y gamma (ppar alfa y gamma)
CN114025847B (zh) 作为tlr信号传导的调节剂的化合物和组合物
CZ288787B6 (cs) N-Substituovaný azabicyklo[3,2,0]heptanový derivát a jeho použití
JPS62267270A (ja) 新規化合物、その製法及びそれを含む医薬組成物
KR20080044273A (ko) 아실구아니딘 유도체 또는 그의 염
SE7501365L (es)
US3769274A (en) Aminophenyl-cycloamidines
ES2821962T3 (es) Bloqueador de canales de sodio
SE435374B (sv) Terapeutiskt aktiva derivat av 4-(2-hydroxi-3-amino-propoxi)-indol, deras framstellning och anvendning.
HUP0203187A2 (hu) Izoxazolszármazékok mint foszfodiészteráz VII inhibitorok és ezeket tartalmazó gyógyszerkészítmények
MXPA02011464A (es) Derivados 1,4-diazepan-2,5-diona y su uso como antagonistas del receptor de la nk-1.
NO160445B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive heterocykliske forbindelser.
US3897443A (en) Pharmacologically active anilinobenzothiazoles

Legal Events

Date Code Title Description
FA Abandonment or withdrawal